Yamane, Tomohiko http://orcid.org/0000-0003-0955-4272
,
Ishii, Kenji
Sakata, Muneyuki
Ikari, Yasuhiko
Nishio, Tomoyuki
Ishii, Kazunari
Kato, Takashi
Ito, Kengo
Senda, Michio
Funding for this research was provided by:
New Energy and Industrial Technology Development Organization
Ministry of Health, Labour and Welfare
J-ADNI Pharmaceutical Industry Scientific Advisory Board Companies
Article History
Received: 13 September 2016
Accepted: 28 November 2016
First Online: 13 December 2016
Compliance with ethical standards
:
: This work is a part of the Translational Research Promotion Project/Research Project for the Development of a Systematic Method for the Assessment of Alzheimer’s Disease, sponsored by the New Energy and Industrial Technology Development Organization of Japan. The Japanese Alzheimer’s Disease Neuroimaging Initiative is also supported by a Grant-in-Aid for Comprehensive Research on Dementia from the Japanese Ministry of Health, Labour and Welfare, as well as by the grants from J-ADNI Pharmaceutical Industry Scientific Advisory Board companies.
: TN has been an employee of Eli Lilly Japan since February 2016. However, all of his effort in the present study had been done when he was a member of Institute of Biomedical Research and Innovation. K. Ito has received research grants from Nihon Medi-Physics Co., Ltd. and a speaker honorarium from Eli Lilly Japan. MS is a principal investigator of clinical trials sponsored by AVID/Eli Lilly and GE Healthcare. MS is also an advisor for AVID/Eli Lilly, GE Healthcare and Piramal Imaging for which fee was paid to the institution.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the each institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Written informed consent was obtained from every subject prior to participation and also from caregiver of the subject categorized as AD or MCI.